Abstract - 594193 Disclosed herein the use of a PDE4 modulator, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof in the manufacture of a medicament to be used in combination with an antituberculosis agent for treating, preventing, or managing tuberculosis, wherein the PDE4 modulator is selected from a compound of formula (I)； a compound of formula (II)； a compound of formula (III)； (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione； cyclopropyl-N-{ 2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindolin-4-yl} carboxamide； cyclopropanecarboxylic acid { 2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl} -amide； or 3-(3,4-dimethoxyphenyl)-3-(1-oxo-1,3-dihydroisoindol-2-yl)propionic acid methylester.
